Edgewise Q2 net loss $36.1M; positive sevasemten data in Becker, Duchenne

Edgewise Therapeutics, Inc.

2025-Q2 EPS reported -$0.77

Net loss of $36.1M ($0.34/share) for Q2 2025; cash and equivalents $594M as of June 30.
MESA trial data: 99% enrollment; NSAA scores stable over 18 months in Becker participants.
Phase 2 LYNX/FOX trials in Duchenne identify 10 mg sevasemten dose for Phase 3; FDA meeting planned Q4 2025.
CIRRUS-HCM (EDG-7500) trial advancing; Part D enrolling; update expected Q4 2025.
GRAND CANYON pivotal trial in Becker fully enrolled; topline data expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.